Novo Nordisk A/S (NVO)
46.60
-0.91
(-1.92%)
USD |
NYSE |
Sep 04, 16:00
46.54
-0.06
(-0.13%)
Pre-Market: 20:00
Novo Nordisk Research and Development Expense (Quarterly) : 1.783B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.783B |
| March 31, 2026 | 1.610B |
| December 31, 2025 | 2.283B |
| September 30, 2025 | 2.410B |
| June 30, 2025 | 1.776B |
| March 31, 2025 | 1.454B |
| December 31, 2024 | 1.974B |
| September 30, 2024 | 1.397B |
| June 30, 2024 | 2.333B |
| March 31, 2024 | 1.253B |
| December 31, 2023 | 1.508B |
| September 30, 2023 | 1.186B |
| June 30, 2023 | 1.041B |
| March 31, 2023 | 969.85M |
| December 31, 2022 | 1.109B |
| September 30, 2022 | 762.28M |
| June 30, 2022 | 732.88M |
| March 31, 2022 | 784.92M |
| December 31, 2021 | 865.53M |
| September 30, 2021 | 673.95M |
| June 30, 2021 | 639.41M |
| March 31, 2021 | 638.75M |
| December 31, 2020 | 718.06M |
| September 30, 2020 | 614.01M |
| June 30, 2020 | 485.96M |
| Date | Value |
|---|---|
| March 31, 2020 | 556.92M |
| December 31, 2019 | 649.66M |
| September 30, 2019 | 536.47M |
| June 30, 2019 | 535.29M |
| March 31, 2019 | 407.41M |
| December 31, 2018 | 694.86M |
| September 30, 2018 | 568.51M |
| June 30, 2018 | 526.95M |
| March 31, 2018 | 548.09M |
| December 31, 2017 | 630.05M |
| September 30, 2017 | 525.58M |
| June 30, 2017 | 505.50M |
| March 31, 2017 | 471.47M |
| December 31, 2016 | 647.55M |
| September 30, 2016 | 518.57M |
| June 30, 2016 | 505.58M |
| March 31, 2016 | 488.27M |
| December 31, 2015 | 591.81M |
| September 30, 2015 | 489.93M |
| June 30, 2015 | 449.90M |
| March 31, 2015 | 490.43M |
| December 31, 2014 | 648.74M |
| September 30, 2014 | 649.63M |
| June 30, 2014 | 565.02M |
| March 31, 2014 | 581.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 3.456B |
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| Novartis AG | 2.759B |